Avalo Therapeutics Inc
NASDAQ:AVTX
Avalo Therapeutics Inc
NASDAQ:AVTX
Price:
14.36 USD
-6.69%
Market Closed
Updated:
May 5, 2024
Avalo Therapeutics Inc
Cash from Operating Activities
|
Avalo Therapeutics Inc
Cash from Operating Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Avalo Therapeutics Inc
NASDAQ:AVTX
|
Cash from Operating Activities
-$30.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
14%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Operating Activities
$8B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
1%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Operating Activities
$8.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Operating Activities
$3.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Operating Activities
$4.6B
|
CAGR 3-Years
21%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
See Also
What is Avalo Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-30.7m
USD
-30.7m
USD
Based on the financial report for Dec 31, 2023, Avalo Therapeutics Inc's Cash from Operating Activities amounts to -30.7m USD.
What is Avalo Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-58%
-58%
Over the last year, the Cash from Operating Activities growth was -15%. The average annual Cash from Operating Activities growth rates for Avalo Therapeutics Inc have been 9% over the past three years , -58% over the past five years .
You don't have any saved screeners yet
